In a recent research article published in BMC Medicine, Nick Scott and colleagues used a mathematical modeling approach to show that vaccination is likely to play a role in reducing hepatitis C prevalence. Here, Dr Scott answers our questions about the study, and explores whether vaccination could help to eliminate the infection.
Nick Scott is an Econometrician at the Burnet Institute in Melbourne, Australia. Since completing his mathematics PhD in 2012, he has been modelling infectious disease transmission among vulnerable populations to inform public health policy.
In most developed settings, new HCV infections and HCV-related liver disease occur among largely disjoint populations. New HCV infections primarily occur among people who inject drugs (PWID) through the sharing of injecting paraphernalia, but the slow progression to liver disease means that the burden of disease is increasingly occurring in an aging population.
Read more.....
Showing posts with label HCV vaccine. Show all posts
Showing posts with label HCV vaccine. Show all posts
Thursday, September 3, 2015
Thursday, August 27, 2015
Cambridge biotech gets funding for development of hepatitis C vaccine
As several biotechs focus on developing lucrative hepatitis C drugs, a Cambridge firm has received funding to help develop a hepatitis C vaccine.
VBI Vaccines (Nasdaq: VBIV) has secured $6.29 million from a variety of venture capital investors, including new investor RTW Investments, with participation from ARCH Venture Partners and Perceptive Advisors.
Under the terms, VBI sold 3 million shares of stock at approximately $2 a share, resulting in the raise.
Read more....
VBI Vaccines (Nasdaq: VBIV) has secured $6.29 million from a variety of venture capital investors, including new investor RTW Investments, with participation from ARCH Venture Partners and Perceptive Advisors.
Under the terms, VBI sold 3 million shares of stock at approximately $2 a share, resulting in the raise.
Read more....
Subscribe to:
Posts (Atom)